Celldex Therapeutics, Inc. (CLDX)
Upgrades & Downgrades
Latest CLDX news
Celldex to Participate in Upcoming November Investor Conferences
10 November 2022
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in No...
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
9 November 2022
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
8 August 2022
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
14 July 2022
Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolima...
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
6 July 2022
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
6 July 2022
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
5 July 2022
Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four pat...
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
4 July 2022
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
22 June 2022
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.